Recently, the national epidemic has risen again, and the situation is more severe and complex. The reporter of China Securities Journal learned that a number of biomedical enterprises on the science and innovation board are still putting into R & D and production at full capacity to meet the needs of prevention and control.
In fact, since the outbreak in early 2020, the biomedical enterprises of the science and innovation board have been on the road of “anti epidemic”. They give full play to their professional advantages in innovative drugs, vaccines and in vitro diagnosis, carry out emergency research, actively fight on the front line of anti epidemic, and bloom hard scientific and technological strength in the “epidemic” one after another.
innovative drugs:
keep pace with the development of world cutting-edge technologies
In the face of the sudden covid-19 epidemic, up to now, more than 10 scientific innovation board pharmaceutical companies have invested in the R & D and production of specific drugs and APIs.
As a pioneer in the development of local innovative drugs, Shanghai Junshi Biosciences Co.Ltd(688180) has invested in the research and development of anti epidemic drugs at the beginning of the outbreak. At present, a variety of R & D pipelines consisting of various anti COVID-19 neutralizing antibody drugs and small molecule oral drugs have been formed.
Shanghai Junshi Biosciences Co.Ltd(688180) headquartered in Pudong New Area, Shanghai. A few days ago, Shanghai announced that it would seal up the area in batches Shanghai Junshi Biosciences Co.Ltd(688180) Board Secretary Chen Yingge told reporters that the company has several R & D centers to coordinate and undertake the R & D work of research projects, which are located in San Francisco, Maryland, Shanghai and Suzhou. At present, the company’s R & D and production are still advancing in an orderly manner. For example, the clinical application of covid-19 oral drug vv116 is being carried out in many centers around the world.
It is reported that based on the positive results of vv116 in the phase I study, Shanghai Junshi Biosciences Co.Ltd(688180) has initiated an international multicenter, double-blind, randomized, placebo-controlled, phase II / III clinical study with partners for mild to moderate covid-19 patients. In addition, an international multicenter, randomized, double-blind, controlled phase III clinical study to evaluate the efficacy and safety of vv116 in patients with moderate and severe covid-19 is ongoing.
As an unprofitable enterprise without product approval at the time of listing, Sinocelltech Group Limited(688520) actively invested in the research and development of covid-19 neutralizing antibody after listing, and plans to raise 2.24 billion yuan through refinancing, of which 457 million yuan will be directly used for the research and development of covid-19 neutralizing antibody. The company is also simultaneously developing recombinant covid-19 virus alpha + beta mutant s trimer protein vaccine. Existing research shows that the product can stimulate stronger and wider spectrum neutralizing antibody titer of mutant strains, and can more effectively resist the infection risk of mutant strains.
vaccine:
build the first barrier against the epidemic
Under the background of continuous repetition and change of the epidemic situation, the research, development and vaccination of vaccines have played a key role in combating the epidemic situation and blocking the transmission. Since the outbreak of the epidemic, domestic vaccine R & D enterprises have worked against the clock, actively invested in this battlefield without gunsmoke, and built a solid barrier against covid-19 epidemic.
For example, the innovative vaccine leader Cansino Biologics Inc(688185) has been continuously invested in vaccine R & D and production in recent years. It is reported that the recombinant New Coronavirus vaccine (adenovirus type 5), jointly developed by the company and the Institute of biotechnology, has been listed in several countries and is approved by many countries such as China, Malaysia and Indonesia as the strengthening needle. It has become the first COVID-19 vaccine approved by China for sequential immunization.
In addition, Cansino Biologics Inc(688185) is further developing inhaled covid-19 vaccine and mRNA covid-19 vaccine. At present, its inhaled covid-19 vaccine is steadily promoting clinical trials. Recently, Cansino Biologics Inc(688185) said on the interactive platform that the company will actively make relevant preparations so that the supply of inhaled covid-19 vaccine products can be realized as soon as possible after being approved, so as to provide protection for the people and establish an immune barrier.
Industry insiders believe that the inhalation covid-19 vaccine product adopts the administration mode of atomization inhalation, which can stimulate the mucosal immune response, which can not be brought about by intramuscular injection. It provides additional protection in the respiratory mucosal tissue, which is expected to provide new ideas for further epidemic prevention and control.
in vitro diagnosis:
efficient scouts racing against viruses
In the race against covid-19, screening and testing are essential. At present, a number of Companies in the in vitro diagnosis industry of science and innovation board have developed covid-19 nucleic acid detection reagent, and innovatively launched a series of scientific and technological anti epidemic products such as rapid nucleic acid detection equipment and respiratory disease joint detection reagent.
For example, Sansure Biotech Inc(688289) needle has developed a rapid nucleic acid detection system, which breaks the bottleneck of application scenarios such as professional laboratories, and promotes nucleic acid detection from the previous “hour level” to “minute level”, with higher sensitivity. At the same time, Sansure Biotech Inc(688289) , Shanghai Zj Bio-Tech Co.Ltd(688317) , Jiangsu Bioperfectus Technologies Co.Ltd(688399) and other companies also developed and issued mobile nucleic acid detection vehicles, which transformed the traditional and immovable PCR laboratory into a movable nucleic acid detection base from sample collection, automatic sample pretreatment, nucleic acid extraction, nucleic acid detection to final report issuance.
With the emergence of virus variants, the speed of virus transmission has accelerated. In order to effectively respond to the changes of the epidemic situation, relevant departments recently decided to take antigen detection as an auxiliary of nucleic acid detection to help rapid screening. So far, the State Food and drug administration has approved the listing of 19 covid-19 antigen self-test reagents, of which 5 are from science and Innovation Board companies.
Zhejiang Orient Gene Biotech Co.Ltd(688298) is one of them. According to public information, Zhejiang Orient Gene Biotech Co.Ltd(688298) covid-19 antigen detection reagent took the lead in fully promoting its use in the European market as early as July 2020, and subsequently obtained market access from the US FDA at the end of December 2021 and Japan recently. On March 15, Zhejiang Orient Gene Biotech Co.Ltd(688298) covid-19 antigen detection reagent obtained the registration certification of Chinese products.
In order to fight the epidemic and support China’s comprehensive economic recovery, Zhejiang Orient Gene Biotech Co.Ltd(688298) relevant people told reporters, “At the first time after obtaining the certificate, the company has contributed millions of people to China’s epidemic prevention donation. At the same time, the company immediately started supporting China’s production capacity, tried its best to overcome the production capacity bottleneck and meet the needs of China’s epidemic prevention and control to the greatest extent. At present, the company’s daily production capacity of covid-19 antigen detection reagent is 18 million people. Recently, the company has quickly supplied tens of millions of covid-19 antigen detection reagents in Shanghai and other places.”p align=”center”>
